Research animal retirement and lifetime care, now available through Alpha Genesis. Professionally managed lifetime care for retired research primates, with expert social reintroduction into stable outdoor groups led by veterinary staff deeply experienced in laboratory-animal medicine.
Learn moreClients
Alpha Genesis supports emerging biotechnology companies that require rodent or NHP studies to answer defined translational, pharmacology, safety, or program-selection questions, with flexible commercial structures for qualified programs.
Alpha Genesis partners with emerging biotechnology companies that need rodent or NHP studies to answer defined translational, pharmacology, safety, or program-selection questions. For the right programs, we offer flexible commercial structures, combining standard terms with deferred or equity-linked options, designed to help promising science move forward on a realistic timeline.
Early preclinical programs often face a timing mismatch: the data that unlocks financing, partnering, or the next decision can require specialized models, veterinary expertise, biospecimens, and regulated infrastructure before a company has raised the capital to run the work at full scale.
When we believe in the science, we're glad to share in the journey. By aligning part of our economics with the value of well-designed preclinical work, we can help make sure a strong study isn't held up waiting on the next round, so you can generate the high-quality data that moves your program forward.
AGI can support emerging-company programs across early in vivo and translational work, with the same scientific and welfare standards applied to every study.
We tailor the commercial structure to your stage, study scope, and goals, from standard terms to deferred or equity-linked options for a portion of study value, and shape an arrangement that works well for both sides.
Every engagement begins with rigorous study design, model selection, and veterinary-led welfare review by board-certified laboratory-animal veterinarians, flexible economics never change study conduct, data quality, or welfare standards. Care is delivered in AAALAC-accredited, USDA-licensed facilities operating within the broader PHS/OLAW-assured framework. (Nothing on this page is an offer to sell or a solicitation to buy any security, or investment, legal, or tax advice; specific terms are agreed together in a definitive written agreement.)
When we believe in a program, we're glad to share in its success. Flexible structures let us align part of our economics with the value of the work, so a well-designed study can move forward on a timeline that fits your stage, not just your balance sheet.
Flexible economics never lower the scientific bar, they raise the stakes for getting the study right. We start where every strong program should: define the question, choose the right model, and design a study that produces clear, decision-grade data.
Our success is tied to yours. We work closely with teams whose science we believe in, bringing veterinary depth, the right models, and audit-ready execution, invested in the data that moves your program toward its next milestone.
Yes. For the right programs, we can structure deferred or equity-linked consideration, such as warrant coverage or SAFE/convertible-note instruments, for a portion of study value, alongside standard terms. We shape each arrangement around your stage and goals and finalize it together in a definitive agreement.
Companies developing therapeutics, vaccines, biologics, devices, or platform technologies that require rodent or NHP research support may contact Alpha Genesis to discuss study design, operational feasibility, and potential partnership structures.
